TYZINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TYZINE (TYZINE).
Imidazoline sympathomimetic amine that stimulates alpha-2 adrenergic receptors in the nasal vasculature, producing vasoconstriction and reducing nasal congestion.
| Metabolism | Primarily hepatic metabolism via oxidation and reduction pathways; no specific CYP enzymes identified. |
| Excretion | Renal elimination of unchanged drug and metabolites accounts for approximately 50% of the dose; fecal elimination is minimal. |
| Half-life | Terminal elimination half-life is approximately 3-4 hours; clinically, this supports dosing every 8-12 hours. |
| Protein binding | Approximately 50% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 1.5 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Intranasal: approximately 100% (local effect); systemic bioavailability is low due to local vasoconstriction limiting absorption. |
| Onset of Action | Intranasal: within 1-2 minutes. |
| Duration of Action | Intranasal: 4-6 hours; repeated use may lead to tachyphylaxis. |
Instill 1-2 drops of 0.1% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Children 6-12 years: Instill 1-2 drops of 0.05% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day. For children under 6: Not recommended. |
| Geriatric use | Use with caution due to increased sensitivity and risk of adverse effects; consider lower concentration (0.05%) and limit duration of use to 3-5 days. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TYZINE (TYZINE).
| Breastfeeding | No data on excretion in breast milk; M/P ratio unknown. Consider risk of infant systemic effects (tachycardia, hypertension) given vasoconstrictor properties. Only use if clearly indicated and monitor infant for adverse effects. |
| Teratogenic Risk | Limited human data; animal studies not conducted. Inadequate evidence for first trimester risk. Avoid during entire pregnancy unless clearly needed. Second and third trimester: no known teratogenicity but risk of maternal hypertension and reduced placental perfusion. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to tetrahydrozoline","Angle-closure glaucoma","Concurrent use with MAO inhibitors or within 14 days of discontinuation"]
| Precautions | ["Rebound congestion (rhinitis medicamentosa) with prolonged use","Potential for systemic effects with excessive use (hypertension, palpitations)","Use caution in cardiovascular disease, hypertension, hyperthyroidism, diabetes, and glaucoma"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure and heart rate due to potential hypertensive effect. Fetal heart rate monitoring if used near term. Assess uterine activity if used intranasally for prolonged duration. |
| Fertility Effects | No data on effect on fertility. Alpha-adrenergic agonists may theoretically impair fallopian tube transport or uterine blood flow. No known direct impact on gamete function. |